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Abstract
We performed a second-generation genome wide association study of 4,533 celiac disease cases
and 10,750 controls. We genotyped 113 selected SNPs with PGWAS<10−4, and 18 SNPs from 14
known loci, in a further 4,918 cases and 5,684 controls. Variants from 13 new regions reached
genome wide significance (Pcombined<5×10−8), most contain immune function genes (BACH2,
CCR4, CD80, CIITA/SOCS1/CLEC16A, ICOSLG, ZMIZ1) with ETS1, RUNX3, THEMIS and
TNFRSF14 playing key roles in thymic T cell selection. A further 13 regions had suggestive
association evidence. In an expression quantitative trait meta-analysis of 1,469 whole blood
samples, 20 of 38 (52.6%) tested loci had celiac risk variants correlated (P<0.0028, FDR 5%) with
cis gene expression.
Celiac disease is a common heritable chronic inflammatory condition of the small intestine
induced by dietary wheat, rye and barley, as well as other unidentified environmental
factors, in susceptible individuals. Specific HLA-DQA1 and HLA-DQB1 risk alleles are
necessary, but not sufficient, for disease development1,2. The well defined role of HLA-DQ
heterodimers, encoded by these alleles, is to present cereal peptides to CD4+ T cells,
activating an inflammatory immune response in the intestine. A single genome wide
association study (GWAS) has been performed in celiac disease, which identified the IL2/
IL21 risk locus1. Subsequent studies probing the GWAS information in greater depth have
identified a further 12 risk regions. Most of these regions contain a candidate gene
functional in the immune system, although only in the case of HLA-DQA1 and HLA-DQB1
have the causal variants been established3-5. Many of the known celiac loci overlap with
other immune-related diseases6. In order to identify additional risk variants, particularly of
smaller effect size, we performed a second-generation GWAS using over six times as many
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samples as the previous GWAS and a denser genome-wide SNP set. We followed up
promising findings in a large collection of independent samples.
The GWAS included five European celiac disease case and control sample collections
including the previously reported celiac disease dataset1. We performed stringent data
quality control (Online Methods), including calling genotypes using a custom algorithm on
both large sample sets, and where possible cases and controls together (Online Methods).
We tested 292,387 non-HLA SNPs from the Illumina Hap300 marker set for association in
4,533 celiac disease cases and 10,750 controls of European descent (Table 1). A further
231,362 additional non-HLA markers from the Illumina Hap550 marker set were tested for
association in a subset of 3,796 celiac disease cases and 8,154 controls. All markers were
from autosomes or the X chromosome. Genotype call rates were >99.9% in both datasets.
The overdispersion factor of association test statistics, λGC=1.12, was similar to that
observed in other GWAS of this sample size7,8. Findings were not substantially altered by
imputation of missing genotypes for 737 celiac disease cases genotyped on the Hap300
BeadChip and corresponding controls (Table 1, collection 1). Here we present results for
directly genotyped samples, as around half the additional Hap550 markers cannot be
accurately imputed from Hap300 data9 (including the new ETS1 locus finding in this study).
Results for the top 1000 markers are available in Supplementary Data 1, but because of
concerns regarding identity detection of individuals10, results for all markers are available
only on request to the corresponding author.
For follow-up, we first inspected genotype clouds for the 417 non-HLA SNPs meeting
PGWAS<10−4, being aware that top GWAS association signals may be enriched for
genotyping artefact, and excluded 22 SNPs from further analysis using a low threshold for
possible bias. We selected SNPs from 113 loci for replication. Markers that passed design
and genotyping quality control included: a) 18 SNPs from all 14 previously identified celiac
disease risk loci (including a tag SNP for the major celiac disease associated HLA-DQ2.5cis
haplotype1); b) 13 SNPs from all 7 novel regions with PGWAS<5×10−7; c) 86 SNPs from 59
of 68 novel regions with 5×10−7> PGWAS >5×10−5 in stage 1; d) 14 SNPs from 14 of 30
novel regions with 5×10−5> PGWAS >10−4 in stage 1 (for this last category, we mostly chose
regions with immune system genes). Two SNPs were selected per region for: regions with
stronger association; regions with possible multiple independent associations; and/or
containing genes of obvious biological interest. We successfully genotyped 131 SNPs in 7
independent follow-up cohorts comprising 4,918 celiac disease cases and 5,684 controls of
European descent. Genotype call rates were >99.9% in each collection. Primary association
analyses of the combined GWAS and follow-up data were performed with a two-sided
2×2×12 Cochran-Mantel-Haenszel test.
RESULTS
Celiac disease risk variants
The HLA locus and all 13 other previously reported celiac disease risk loci showed evidence
for association at a genome wide significance threshold (Pcombined<5×10−8) (Table 2). We
note that some loci were previously reported using less stringent criteria (e.g. the P<5×10−7
recommended by the 2007 WTCCC study11), but that in the current, much larger sample
set, all known loci meet recently proposed P<5×10−8 thresholds12,13.
We identified 13 novel risk regions with genome-wide significant evidence (Pcombined
<5×10−8) of association, including regions containing the BACH2, CCR4, CD80, CIITA/
SOCS1/CLEC16A, ETS1, ICOSLG, RUNX3, THEMIS, TNFRSF14, and ZMIZ1 genes
which are of obvious immunological function (Table 2). A further 13 regions met
‘suggestive’ criteria for association (either 10−6> Pcombined >5×10−8 and/or PGWAS<10−4
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and Pfollowup<0.01). These regions also contain multiple genes of obvious immunological
function, including CD247, FASLG/TNFSF18/TNFSF4, IRF4, TLR7/TLR8, TNFRSF9 and
YDJC. Six of the 39 non-HLA regions show evidence for the presence of multiple
independently associated variants in a conditional logistic regression analysis
(Supplementary Table 2).
We tested the 40 SNPs with the strongest association (Table 2) from each of the known
genome-wide significant, new genome-wide significant, and new suggestive loci for
evidence of heterogeneity across the 12 collections studied. Only the HLA region was
significant (Breslow-Day test P<0.05 / 40 tests, rs2187668 P=4.8×10−8) which is consistent
with the well described North-South gradient in HLA allele frequency in European
populations, and more specifically for HLA-DQ in celiac disease14.
We observed no evidence for interaction between each of the 26 genome-wide significant
non-HLA loci, which is consistent with what has been reported for complex diseases so far.
However, we did observe weak evidence for lower effect sizes at non-HLA loci in high risk
HLA-DQ2.5cis homozygotes, similar to what has been previously observed in type 1
diabetes7.
To obtain more insight into the functional relatedness of the celiac loci, we applied GRAIL,
a statistical tool that utilizes text mining of PubMed abstracts to annotate candidate genes
from loci associated with common disease risk15,16. In order to assess the sensitivity of this
tool (using known loci as a positive control), we first performed a ‘leave-one-out’ analysis
of the 27 genome-wide significant celiac disease loci (including HLA-DQ). GRAIL scores
of Ptext<0.01 were obtained for 12 of the 27 loci (44% sensitivity, Table 2). Factors that
limit the sensitivity of GRAIL include biological pathways being both known (a 2006
dataset is used to avoid GWAS era studies), and published in the literature. We then applied
GRAIL analysis, using the 27 known regions as a seed, to all 49 regions (49 SNPs) with
10−3 >Pcombined >5×10−8 and obtained GRAIL Ptext <0.01 for 9 regions (18.4%). As a
control, only 5.5% (279 of 5033) of randomly selected Hap550 SNPs reached this threshold.
In addition to the five ‘suggestive’ loci shown in Table 2, GRAIL annotated four further
interesting gene regions of lower significance in the combined association results: rs944141/
PDCD1LG2 (Pcombined=4.4×10−6), rs976881/TNFRSF8(Pcombined =2.1×10−4), rs4682103/
CD200/BTLA(Pcombined=6.8×10−6) and rs4919611/NFKB2 (Pcombined=6.1×10−5). There
appeared to be further enrichment for genes of immunological interest which are not GRAIL
annotated in the 10−3>Pcombined>5×10−8 significance window, including rs3828599/TNIP1
(Pcombined=1.55×10−4), rs8027604/PTPN9 (Pcombined=1.4×10−6), rs944141/CD274
(Pcombined=4.4×10−6). Some of these findings, for which neither genome-wide significant
nor suggestive association is achieved, are likely to comprise part of a longer tail of disease
predisposing common variants, of weaker effect sizes. Definitive assessment of these
biologically plausible regions would require genotyping and association studies using much
larger sample collections than the present study.
We previously showed considerable overlap between celiac disease and type 1 diabetes risk
loci17, as well as celiac disease and rheumatoid arthritis18, and more generally, there is now
substantial evidence for shared risk loci between the common chronic immune mediated
diseases6. To update these observations, we searched ‘A Catalog of Published Genome
Wide Association Studies’ (18 Nov 2009)19 and the HuGE database20. We found some
evidence (requiring a published association report of P<1×10−5) of shared loci with at least
one other inflammatory or immune mediated disease for 18 of the current 27 genome-wide
significant celiac risk regions. We defined shared regions as the broad LD block, however
different SNPs are often reported in different diseases, and at only three of the 18 shared
regions are associations across all diseases with the same SNP or a proxy SNP in r2>0.8 in
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HapMap CEU. Currently 9 regions appear celiac disease specific and may reflect distinctive
disease biology including the regions containing rs296547 and rs9792269, and the regions
around CCR4, CD80, ITGA4, LPP, PLEK, RUNX3 and THEMIS. In fact, locus sharing
between diseases is probably greater, due to both stochastic variation in results from sample
size limitations, and regions with a genuinely stronger effect size in one disease and weaker
effect size in another.
Genetic variation in ETS1 has recently been reported to be associated with systemic lupus
erythematosus (SLE) in the Chinese population, although is not associated with SLE in
European populations21. The most strongly associated celiac (European population) SNP
rs11221332 and the most strongly associated SLE (Chinese population) SNP rs6590330 map
70kb apart. Inspection of the HapMap phase II data shows broadly similar linkage
disequilibrium patterns between Chinese (CHB) and European (CEU) populations in this
region, with the two associated SNPs in separate non-adjacent linkage disequilibrium
blocks. Thus distinct common variants within the same gene are predisposing to different
autoimmune diseases across different ethnic groups.
Function of celiac risk variants
Celiac risk variants in the HLA alter protein structure and function4. However we identified
only four non-synonymous SNPs with evidence for celiac disease association
(PGWAS<10−4) from the other 26 genome-wide significant associated regions (rs3748816/
MMEL1, rs3816281/PLEK, rs196432/RUNX3, rs3184504/SH2B3). Although
comprehensive regional resequencing is required to test the possibility that coding variants
contribute to the observed association signals, more subtle effects of genetic variation on
gene expression are the more likely major functional mechanism for complex disease genes.
With this in mind, we performed a meta-analysis of new and published genome-wide
expression quantitative trait loci (eQTL) datasets comprising 1,469 human whole blood
(PAXgene) samples reflecting primary leucocyte gene expression. We applied a new
method, Transcriptional Components, to remove a substantial proportion of inter-individual
non-genetic expression variation and performed eQTL meta-analysis on the residual
expression variation (Online Methods).
We assessed 38 of the 39 genome-wide significant and suggestive celiac disease associated
non-HLA loci (Table 2) for cis expression - genotype correlations. We tested the SNP with
the strongest association from each region. However for five regions the most associated
SNP was not genotyped in the eQTL samples (Hap300 data), instead for four of these we
tested a proxy SNP (r2>0.5 in HapMap CEU). In addition, for six loci showing evidence of
multiple independent associations in conditional regression analyses, we tested a second
SNP showing independent celiac disease association for eQTL analysis. In total we assessed
44 independent non-HLA SNP associations in peripheral whole blood samples genotyped on
the Illumina Hap300 BeadChip and either Illumina Ref8 or HT12 expression arrays,
correlating each SNP with data from gene-probes mapping within a 1Mb window.
We identified significant (Spearman P<0.0028, corresponding to 5% false discovery rate)
eQTLs at 20 of 38 (52.6%) non-HLA celiac loci tested (Table 3, Supplementary Figures 2 &
3). Some loci had evidence of eQTLs with multiple probes, genes or SNPs (Table 3). We
assessed whether the number of SNPs with cis-eQTL effects out of the 44 SNPs that we
tested, was significantly higher than expected. We observed that eQTL SNPs on average
have a substantially higher MAF than non-eQTL SNPs in the 294,767 SNPs tested. In order
to correct for this we selected 44 random SNPs that had an equal MAF distribution, and
determined for how many of these MAF-matched SNPs eQTLs were observed. We observed
a significantly higher number of eQTL SNPs (P=9.3 × 10−5, 106 permutations) amongst the
celiac associated SNPs than expected by chance (22 observed eQTL SNPs, vs. 7.8 expected
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eQTL SNPs). Therefore the celiac disease associated regions are greatly enriched for
eQTLs. These data suggest some risk variants may influence celiac disease susceptibility
through a mechanism of altered gene expression. Candidate genes with a significant eQTL,
where the peak eQTL signal and peak case/control association signal are similar
(Supplementary Figure 3), include MMEL1, NSF, PARK7, PLEK, TAGAP, RRP1,
UBE2L3 and ZMIZ1.
We also assessed co-expression of genes mapping within 500kb of SNPs showing strongest
case/control association from the 40 genome-wide significant and suggestive celiac disease
loci in an analysis of the 33,109 human Affymetrix Gene Expression Omnibus dataset. This
analysis loses power to detect tissue specific correlations by use of numerous tissue types,
but greatly gains power by the large sample size. We detected several distinct co-expression
clusters (Pearson correlation coefficient between genes >0.5), including four clusters of
immune-related genes which contain at least one gene from 37 of the 40 genome-wide
significant and suggestive loci (Fig. 1). These data further demonstrate that genes from
celiac disease risk loci map to multiple distinct immunological pathways involved in disease
pathogenesis.
DISCUSSION
We previously reported that most celiac genetic risk variants mapped near genes that are
functional in the immune system22, and this remains true for the 13 new genome-wide
significant, and 13 new suggestive, risk variants from the current study. We can now refine
these observations and highlight specific immunological pathways relevant to celiac disease
pathogenesis:
1) T cell development in the thymus
The rs802734 LD block contains the recently identified gene THEMIS ‘THymus-Expressed
Molecule Involved in Selection’. THEMIS plays a key regulatory role in both positive and
negative T-cell selection during late thymocyte development23. Furthermore, the
rs10903122 LD block contains RUNX3, a master regulator of CD8+ T lymphocyte
development in the thymus24,25. TNFRSF14 (LIGHTR, rs3748816 LD block) has
widespread peripheral leucocyte functions as well as a critical role in promoting thymocyte
apoptosis26. The ETS1 transcription factor (rs11221332 LD block) is also active in
peripheral leucocytes, however it is also a key player in thymic CD8+ lineage differentiation,
acting in part by promoting RUNX3 expression27.
The importance of the thymus in autoimmune disease pathogenesis has been previously
emphasised by the established role of thymectomy in the treatment of myasthenia gravis. In
type 1 diabetes, it was shown that disease associated genetic variation in the insulin gene
INS causes altered thymic insulin expression and subsequent T cell tolerance for insulin as a
self-protein28. However, the importance of thymic T cell regulation has not been previously
recognised in the aetiology of celiac disease. It is conceivable that the associated variants
may alter biological processes prior to thymic MHC-ligand interactions. Alternatively it is
now clear that exogenous antigen presentation and selection occurs in the thymus via
migratory dendritic cells - this has been demonstrated for skin, and has been hypothesised
for food antigens29,30. These findings suggest research into immuno-/pharmaco-logical
modifiers of T cell tolerance more generally in autoimmune diseases.
2) Innate immune detection of viral RNA
Although the association signal at rs5979785 (Pcombined=6.36×10−8) in the TLR7/TLR8
region is just outside our genome wide significance threshold, we observe a strong effect of
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rs5979785 on TLR8 expression in whole blood. Both TLRs recognise viral RNA. Taken
together with the recent observation of rare loss of function mutations in the enteroviral
response gene IFIH1 protective against type 1 diabetes31, these findings suggest viral
infection (and the nature of the host response to infection) as a putative environmental
trigger common to these autoimmune diseases.
3) T and B cell co-stimulation (or co-inhibition)
This class of molecules controls the strength and nature of the response to T or B
(immunoglobulin) cell receptor activation by antigens. We observe multiple regions with
genes (CTLA4/ICOS/CD28, TNFRSF14, CD80, ICOSLG, TNFRSF9, TNFSF4) from this
class of ligand-receptor pairs suggesting fine control of the adaptive immune response might
be altered in at-risk individuals.
4) Cytokines, chemokines and their receptors
Our previous report discussed the function of the 2q11-12 interleukin receptor cluster
(IL18RAP, etc), the 3p21 chemokine receptor cluster (CCR5, etc.) and the loci containing
IL2/IL21 and IL12A22. We now report additional loci containing TNFSF18 and CCR4.
We estimate that the current celiac disease variants, including the major celiac disease
associated HLA variant, HLA-DQ2.5cis, less common celiac disease associated haplotypes
in the HLA (HLA-DQ8; HLA-DQ2.5trans; HLADQ2.2), and the additional 26 definitively
implicated loci explain about 20% of total celiac disease variance, which would represent
40% of genetic variance, assuming a heritability of 0.5. A long tail of low effect size
common variants, along with highly penetrant rare variants (both at the established loci and
elsewhere in the genome), may substantially contribute to the remaining heritability.
We observed different haplotypes within the ETS1 region associated with coeliac disease in
Europeans, and SLE in the Chinese population. We further note for some autoimmune
diseases studied in European origin populations, that although the same LD block has been
associated, the association is with a different haplotype. In some cases, the same variants are
associated, but the direction of association is opposite (e.g. rs917997/IL18RAP in celiac
disease versus type 1 diabetes). We believe further exploration of these signals may reveal
critical differences in the nature of the immune system perturbation between these diseases.
Previous investigators have observed that only a small proportion of GWAS associations are
coding variants, and have suggested that these may instead influence regulation of gene
expression. Here, we show that over half the celiac disease associated variants are correlated
with expression changes in nearby genes. This mechanism is likely to explain the function of
some risk variants for other common, complex diseases. Further research, however, is
needed to definitively determine at each locus both the celiac disease causal variants and
their functional mechanisms.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
METHODS
Subjects
Written informed consent was obtained from all subjects, with Ethics Committee /
Institutional Review Board approval. All individuals are of European ancestry. Affected
celiac individuals were diagnosed according to standard clinical, serological and
histopathological criteria including small intestinal biopsy. DNA samples were from blood,
lymphoblastoid cell lines or saliva. A more detailed description of subjects is provided in
Supplementary Information.
GWAS genotyping
See Table 1. UK(1) case and control genotyping was previously described1,7. Illumina 670-
Quad and 1.2M-Duo (custom chips designed for the WTCCC2 and comprising Hap550 / 1M
and common CNV content) and 610-Quad genotyping was performed in London, Hinxton
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and Groningen. Bead intensity data was normalized for each sample in BeadStudio, R and
theta values exported and genotype calling performed using a custom algorithm1,35. A
detailed description of genotype calling steps is provided in Supplementary Information.
Quality control steps were performed in the following order: Very low call rate samples and
SNPs were first excluded. SNPs were excluded from all sample collections if any collection
showed call rates were <95% or deviation from Hardy-Weinberg equilibrium (P<0.0001) in
controls. Samples were excluded for call rate <98%, incompatible recorded gender and
genotype inferred gender, ethnic outliers (identified by multi-dimensional scaling plots of
samples merged with HapMap Phase II data), duplicates and first degree relatives. 22 of 417
SNPs showing apparent association (PGWAS <10−4) were excluded after visual inspection of
R theta plots suggested possible bias.
The over-dispersion factor of association test statistics (genomic control inflation factor),
λGC, was calculated using observed versus expected values for all SNPs in PLINK.
Follow-up genotyping
See Table 1. Finnish controls (12) were genotyped on the 610-Quad BeadChip, other
samples were genotyped using Illumina GoldenGate BeadXpress assays in London, Hinxton
and Groningen. Genotyping calling was performed in BeadStudio for combined cases and
controls in each separate collection, with the exception of the Finnish collection, and whole
genome amplified samples (89 Irish cases and 106 Spanish controls). Quality control steps
were performed as for the GWAS. 131 of 144 SNPs passed quality control and visual
inspection of genotype clouds.
SNP association analysis
Analyses were performed using PLINK v1.0736, mostly using the Cochran-Mantel-Haenzel
test. Logistic regression analyses were used to define the independence of association
signals within the same linkage disequilibrium block, with group membership included as a
factorized covariate
Genotype imputation was performed for samples genotyped on the Hap300 using BEAGLE
and CEU, TSI, MEX and GIH reference samples from HapMap3. Association analysis was
performed using logistic regression on posterior genotype probabilities, with group
membership included as a factorized covariate.
Structured association tests were performed using PLINK, as described using genetically
matched cases and controls within collections identified by identity by state similarity across
autosomal non-HLA SNPs as described34 (settings --ppc 0.001 --cc, clusters constrained by
the 5 collections). Principal components analysis was performed using EIGENSTRAT and a
set of 12,810 autosomal non-HLA SNPs chosen for low LD and ancestry information37,38,
association tests were corrected for the top 10 principal components and combined using
weighted Z scores.
The fraction of additive variance was calculated using a liability threshold model39
assuming a population prevalence of 1%. Effect sizes and control allele frequencies were
estimated from the combined replication panel. Genetic variance was calculated assuming
50% heritability.
GRAIL analysis
We performed GRAIL analysis (http://www.broadinstitute.org/mpg/grail/grail.php) using
HG18 and Dec2006 PubMed datasets, default settings for SNP rs number submission, and
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the 27 genome-wide significant celiac disease risk loci (most associated SNP) as seeds. As a
query we used either associated SNPs, or 101 × 50 randomly chosen Hap550 SNP datasets
(5050 SNPs, of which 5033 mapped to the GRAIL database).
Identification of Transcriptional Components
We noted that the power of eQTL studies in humans is limited by substantial observed inter-
individual variation in expression measurements due to non-genetic factors, and therefore
developed a method, Transcriptional Components, to remove a large component of this
variation (manuscript in preparation). Expression data from 42,349 heterogeneous human
samples hybridized to Affymetrix HG-U133A (GEO accession number: GPL96) or HG-
U133 Plus 2.0 (GEO accession number: GPL570) Genechips were downloaded 40 (Fig. 1,
step 1). Samples missing data for >150 probes were excluded, and only probes available on
both platforms were analysed, resulting in expression data for 22,106 probes and 41,408
samples. We performed quantile normalization using the median rank distribution41 and
log2 transformed the data - ensuring an identical distribution of expression signals for every
sample, discarding previous normalization and transformation steps.
Initial quality control (QC) was performed by applying principal component analysis (PCA)
on the sample correlation matrix (pair-wise Pearson correlation coefficients between all
samples). The first principal component (PC), explaining ~80-90% of the total
variance42,43, describes probe-specific variance. 6,375 samples with correlation R < 0.75 of
the sample array with this PC were considered outliers of lesser quality and excluded from
analysis. We excluded entire GEO datasets where >25% of the samples were outliers
(probably expression ratios versus a reference, not absolute data). The final dataset
comprised 33,109 samples (17,568 GPL96 and 15,541 GPL570 samples), and we repeated
the normalization and transformation on the originally deposited expression values of these
post-quality control samples.
We next applied PCA on the pairwise 22,106 × 22,106 probe Pearson correlation coefficient
matrix assayed on the 33,109 sample dataset (our fast C++ tool, MATool, is available upon
request), attempting to simplify the structure of the data. Here, PCA represents a
transformation of a set of correlated probes into sets of uncorrelated linear additions of
probe expression signals (eigenvectors) that we name Transcriptional Components (TCs).
Each TC is a weighted sum of probe expression signals and eigenvector probe coefficients.
These TC-scores can be calculated for each observed expression array sample (reflecting the
TC activity per sample).
Subjects for expression - genotype correlation
We obtained peripheral blood DNA and RNA (PAXgene) from Dutch and UK individuals
who were disease cases or controls for GWAS studies (Supplementary Table 1). All samples
had been genotyped for a common SNP set on Illumina platforms. Analysis was confined to
294,767 SNPs that had a MAF ≥ 5%, call-rate ≥ 95% and exact HWE P>0.001. RNA from
the samples was either hybridized to Illumina HumanRef-8 v2 arrays (229 samples,
Ref-8v2) or Illumina HumanHT-12 arrays (1,240 samples, HT-12), and raw probe intensity
extracted using BeadStudio. The Ref-8v2 samples were jointly quantile normalized and log2
transformed, and similarly for the HT-12 samples. Subsequent analyses were also conducted
separately for these datasets, up to the eventual eQTL mapping, that uses a meta-analysis
framework, combining eQTL results from both arrays. HT-12 and Ref-8v2 arrays are
different, but share many probes with identical probe sequences. Illumina sometimes use
different probe identifiers for the same probe sequences - in meta-analysis and Table 3, the
label HT-12 was used if both HT-12 and Ref-8v2 had the same sequence.
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Re-mapping of probes
If probes mapped incorrectly, or cross-hybridized to multiple genomic loci, it might be that
an eQTL would be detected that would be deemed a trans-eQTLs. To prevent this, we used a
mapping approach versus a known reference that we developed for high-throughput short
sequence RNAseq data44. We took the DNA sequence as synthesised for each cDNA probe,
and aligned it versus a transcript masked gDNA genome combined with cDNA sequences.
A more detailed description of probe re-mapping is provided in Supplementary
Information. Probes that did not map, or mapped to multiple different locations were
removed.
Affymetrix transcriptional components applied to Illumina expression data
TC-scores can be inferred in new (non-Affymetrix) datasets for every new individual
sample. For the Illumina samples (used for the cis-eQTL mapping), only Illumina probes
that could be mapped to any of our 22,106 Affymetrix probes were used
(www.switchtoi.com/probemapping.ilmn). The TC-score of sample i for the jth TC is
defined as:  , where vtj is defined as the tth Affymetrix probe
coefficient for the jth TC; ati is the Illumina expression measurement for the tth mapped
probe for sample i. We inferred the Illumina TC-scores for the top 1,000 TCs.
Removal of transcriptional component effects from Illumina expression data
Because our Illumina eQTL dataset (n = 1,469) is much less heterogeneous than the
Affymetrix dataset (n = 33,109), we expect that some TCs will hardly vary. We therefore
performed a PCA on the covariance matrix of the top 1,000 inferred TC-scores for the
Illumina dataset to effectively compress the TC data into a small set of ‘aggregate TCs’
(aTCs). As aTCs are orthogonal, we used linear regression to eliminate the effect of the top
50 aTCs. We correlated the TC-scores for each peripheral blood sample with probe
expression levels. We then used the resulting residual gene expression data for subsequent
cis-eQTL mapping.
cis-eQTL mapping
We used the residual gene expression data (Fig. 1) in a meta-analysis framework, as
described45,46. In brief, analyses were confined to those probe-SNP pairs for which the
distance from probe transcript midpoint to SNP genomic location was less than 500 kb. To
prevent spurious associations due to outliers, a non-parametric Spearman’s rank correlation
analysis was performed. When a particular probe-SNP pair was present in both the HT12
and H8v2 datasets, an overall, joint p-value was calculated using a weighted Z-method
(square root of the dataset sample number). To correct for multiple testing we controlled the
false discovery rate (FDR). The distribution of observed P values was used to calculate the
FDR, by permuting expression phenotypes relative to genotypes 1000 times within the
HT12 and H8v2 dataset. Finally, we removed any probes from analysis which contain a
known SNP (1000Genomes CEU SNP data, April 2009 release).
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Figure 1. Co-expression analysis of genes mapping to 40 genome-wide significant and suggestive
celiac disease regions in 33,109 heterogenous human samples from the Gene Expression
Omnibus
Genes mapping within a 1Mb window of associated SNPs (Table 2) were tested for
interaction with genes from other loci. Interactions with Pearson correlation >0.5 shown
(P<10−100). Only the genes known to contain causal mutations (HLA-DQA1, HLA-DQB1)
were analysed from the HLA region, “HLA-DQB2 / HLA-DQB1” is a single expression
probeset mapping to both genes. No probe for THEMIS was present on the earlier version of
the U133 array, however in a subset analysis of U133 Plus2.0 data, THEMIS is co-expressed
in the major immune gene cluster
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